These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562 [TBL] [Abstract][Full Text] [Related]
66. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Drake WM; Parkinson C; Besser GM; Trainer PJ Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543 [TBL] [Abstract][Full Text] [Related]
67. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326 [TBL] [Abstract][Full Text] [Related]
68. [Treatment of acromegaly]. Dénes J; Korbonits M; Hubina E; Góth M Orv Hetil; 2010 Aug; 151(34):1384-93. PubMed ID: 20705553 [TBL] [Abstract][Full Text] [Related]
74. GH receptor antagonist: mechanism of action and clinical utility. Surya SK; Barkan AL Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909 [TBL] [Abstract][Full Text] [Related]
75. New formulations and approaches in the medical treatment of acromegaly. Debono M; Newell-Price J Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):350-5. PubMed ID: 20502324 [TBL] [Abstract][Full Text] [Related]
76. Pegvisomant: new preparation. A last resort in acromegaly. Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152 [TBL] [Abstract][Full Text] [Related]
77. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Drake WM; Berney DM; Kovacs K; Monson JP Eur J Endocrinol; 2005 Aug; 153(2):203-5. PubMed ID: 16061824 [TBL] [Abstract][Full Text] [Related]
78. Experience from the Argentine Pegvisomant Observational Study: preliminary data. García Basavilbaso N; Guitelman M; Nagelberg A; Stalldecker G; Carabelli A; Bruno O; Danilowitz K; Manavela M; Mallea Gil S; Ballarino C; Guelman R; Katz D; Fidalgo S; Leal R; Fideleff H; Servidio M; Bruera D; Librandi F; Chervin A; Vitale M; Basso A Front Horm Res; 2010; 38():42-49. PubMed ID: 20616494 [TBL] [Abstract][Full Text] [Related]
79. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297 [TBL] [Abstract][Full Text] [Related]
80. Pegvisomant and improvement of quality of life in acromegalic patients. Neggers SJ; van der Lely AJ Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]